| Original language | English (US) |
|---|---|
| Pages (from-to) | 227-228 |
| Number of pages | 2 |
| Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
| Volume | 1792 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2009 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1792, No. 4, 04.2009, p. 227-228.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Cellular immortality and cancer
T2 - From telomerase to cancer stem cells
AU - Shay, Jerry
AU - Keith, W. Nicol
N1 - Funding Information: W. Nicol Keith obtained his undergraduate training in genetics at Edinburgh University before undertaking his Ph.D. studies at the CRUK Beatson Institute for Cancer Research in Glasgow. After post-doctoral research in areas related to cancer drug resistance, he established his research program in the Department of Medical Oncology at Glasgow University. In 2004, he became Professor of Molecular Oncology at the Centre for Oncology and Applied Pharmacology of Glasgow University. Professor Keith's program brings together the key strategic areas of cellular immortality and senescence with the regulation of gene expression. The overall objective of his work is to carry out translational research extending the identification of basic mechanisms of gene regulation into validated targets for new therapeutics. Telomerase activity is vital for tumor progression. Through his research program, the group have discovered and characterized the key promoter sequences, which switch on/off telomerase RNA gene expression. This discovery has been used to develop a detailed understanding of the molecular mechanisms influencing telomerase activity and how cancer cells become immortal. Professor Keith's group focuses on exploiting their unique understanding of cancer cell immortality to develop novel cancer therapeutics, including small molecule drugs. His research is currently supported by grants from Cancer Research UK, European Community, and Glasgow University. Nicol is a member of several national and international scientific committees and is particularly active within the International Union Against Cancer (UICC), including chairing the UICC International Cancer Technology Transfer Fellowships (ICRETT) grants committee, which facilitates rapid international transfer of cancer research techniques and technology and clinical management skills across the globe.
PY - 2009/4
Y1 - 2009/4
UR - http://www.scopus.com/inward/record.url?scp=64549117386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64549117386&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2009.03.006
DO - 10.1016/j.bbadis.2009.03.006
M3 - Editorial
AN - SCOPUS:64549117386
SN - 0925-4439
VL - 1792
SP - 227
EP - 228
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 4
ER -